Vertex aims to further bolster its gene-editing therapy pipeline by using Orna's lipid nanoparticle delivery technologies during the three-year collaboration.

Aviceda Therapeutics has secured $207.5 million in series C funds as the immunomodulator-focused biotech awaits a phase 3 ...

To schedule a meeting, contact Mike Moyer at mmoyer@lifesciadvisors.com ...

Epstein-Barr virus (EBV) causes infectious mononucleosis and is associated with several types of cancer and multiple sclerosisThere are no current treatments or vaccines for EBVFirst participant dosed ...

Vertex is paying Orna $65 million upfront, in part via convertible note, according to a Jan. 7 release. Orna—which acquired ...

The researcher has given an overview on the regulatory network of extracellular circRNAs in cancer and their impact on cancer drug resistance.

NanoImaging Services ("NIS"), the leading provider of cryo-electron microscopy ("cryo-EM") services for drug discovery and ...

Novel peptide-modified lipid nanoparticles can cross the blood–brain barrier and target neurons, taking one step closer to ...

Paclitaxel is under clinical development by InnoUp Farma and currently in Phase I for Solid Tumor. According to GlobalData, Phase I drugs for Solid Tumor have a 69% phase transition success rate (PTSR ...

The science has proven that gene therapies are effective treatments, and they have given hope to patients and their families ...

Liver siRNA is under clinical development by Nitto BioPharma and currently in Phase II for Liver Cancer. According to GlobalData, Phase II drugs for Liver Cancer have a 31% phase transition success ...